cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.5517/ccdc.csd.cc275yr4
title: CCDC 2061306: Experimental Crystal Structure Determination

description: Related Article: K. Roszak, A. Katrusiak|2021|Acta Crystallogr.,Sect.B:Struct.Sci.,Cryst.Eng. and Mat.|77|449|doi:10.1107/S205252062100398X
DOI: 10.23636/402
title: Resources used in attribution of early German Bookbindings in the British Library

description: This list of resources relates to the Early German Bookbindings in the British Library set. See the documents linked in the 'Related URL' field for more information.
DOI: 10.6084/m9.figshare.14730435
title: Analysis of DNA methylation profile of Korean CLL patients with MBD-Seq

description: In this study, we performed genome-wide methylation profiling of eight CLL patients and five control subjects, in an Asian cohort. Methyl-CpG-binding domain sequencing (MBD-Seq) was used as the profiling method. Differential methylation analysis identified a number of differentially methylated regions (DMRs) and genes (DMGs). More regions were hypomethylated than were hypermethylated. Promoters contained the largest proportion of DMRs, while distal intergenic and intron regions contained the largest number of DMRs. Gene Ontology, pathway analysis, and network-based prioritization of DMGs were also performed.
DOI: 10.6084/m9.figshare.14730435.v1
title: Analysis of DNA methylation profile of Korean CLL patients with MBD-Seq

description: In this study, we performed genome-wide methylation profiling of eight CLL patients and five control subjects, in an Asian cohort. Methyl-CpG-binding domain sequencing (MBD-Seq) was used as the profiling method. Differential methylation analysis identified a number of differentially methylated regions (DMRs) and genes (DMGs). More regions were hypomethylated than were hypermethylated. Promoters contained the largest proportion of DMRs, while distal intergenic and intron regions contained the largest number of DMRs. Gene Ontology, pathway analysis, and network-based prioritization of DMGs were also performed.
DOI: 10.6084/m9.figshare.14730522
title: Datasets.xlsx

description: Datasets to be uploaded after publication
DOI: 10.5281/zenodo.4898928
title: UAV bugs dataset and taxonomy

description: This data set contains 569 real world bugs, 168 UAV-specific bugs and their taxonomy. Our replication package consists of two maim folders:bugSet and bugTaxonomy bugSet In this folder we have placed all the bugs that we have indentified from PX4 and Ardupilot on GitHub. Data collection process is explained in detail in Section 3.1 of the paper. Each line in bugSet.xlsx provides project name and the link of 569 real-world bugs. bugTaxonomy Our manual analysis was conducted in 3 iterations(Section 3.2 in the paper). In each file(3 iterations) we provide the following information: (a) Project name;(b)Bug link; (c)bug label or bug description.
DOI: 10.6084/m9.figshare.14730060
title: Supplementary Material for: Clinical Relevance of Shrimp Sensitization in Patients with Allergic Rhinitis: Anti-Der p 10 IgE as Predictor

description: <b><i>Introduction:</i></b> Cross-reactivity between shrimp and house dust mite (HDM) proteins has been widely documented. In tropical region, shrimp (5–15%) and mite sensitization (80–95%) is prevalent in allergic patients. However, the clinical relevance of shrimp sensitization in patients with allergic rhinitis (AR) has been poorly studied. The aim of this study was to determine the prevalence and the clinical relevance shrimp IgE sensitization in AR patients sensitized to <i>Dermatophagoides pteronyssinus.</i> <b><i>Methods:</i></b> The study was conducted in Medellin (Colombia). A cross-sectional study in patients with AR sensitized to HDM was performed in 3 steps: (i) assessment of IgE sensitization frequency to shrimp <i>Penaeus azteca</i>, <i>Litopenaeus vannamei,</i> and tropomyosin homologous allergens rDer p 10, rPen a 1, and rLit v 1, (ii) evaluation of the clinical relevance of shrimp sensitization using oral challenge test (OCT) and (iii) identification of possible risk factors for positive-OCT results. Ethical committee approval was obtained. <b><i>Results:</i></b> From 443 patients with AR, 86 (19.4%) were sensitized to shrimp and 23 of them (26.7%) had shrimp allergy diagnosis. Thirty-six of the patients sensitized to shrimp (41.2%) reported not previously consumed this food and eleven of them had a positive-OCT (30.5%). There was not statistically significant difference in total IgE or sIgE (<i>D. pteronyssinus, P. azteca, L. vannamei</i>, rPen a 1, and rLit v 1) between OCT groups (positive vs. negative results). Anti-Der p 10 IgE was associated with risk for a positive-OCT in different multivariable scenarios. <b><i>Discussion/Conclusion:</i></b> Our results suggest that in patients with HDM-associated AR and shrimp IgE sensitization is necessary to evaluate the clinical relevance of shrimp IgE even if the patient has never consumed shrimp because of cross-reactivity. Anti-Der p 10 could be a possible biomarker of clinical relevance to shrimp sensitization and could reduce the need for OCTs.
DOI: 10.6084/m9.figshare.14730393
title: Supplementary Material for: Sex-Specific Long-Term Trends in Length of Hospital Stay, Postmenstrual Age at Discharge, and Survival in Very Low Birth Weight Infants

description: <b><i>Introduction:</i></b> In very low birth weight (&lt;1,500 g, VLBW) infants, morbidity and mortality have decreased substantially during the past decades, and both are known to be lower in girls than in boys. In this study, we assessed sex-specific changes over time in length of hospital stay (LOHS) and postmenstrual age at discharge (PAD), in addition to survival in VLBW infants. <b><i>Methods:</i></b> This is a single-center retrospective cohort analysis based on quality assurance data of VLBW infants born from 1978 to 2018. Estimation of sex-specific LOHS over time was based on infants discharged home from neonatal care or deceased. Estimation of sex-specific PAD over time was based on infants discharged home exclusively. Analysis of in-hospital survival was performed for all VLBW infants. <b><i>Results:</i></b> In 4,336 of 4,499 VLBW infants admitted from 1978 to 2018 with complete data (96.4%), survival rates improved between 1978–1982 and 1993–1997 (70.8 vs. 88.3%; hazard ratio (HR) 0.20, 95% confidence interval 0.14, 0.30) and remained stable thereafter. Boys had consistently higher mortality rates than girls (15 vs. 12%, HR 1.23 [1.05, 1.45]). Nonsurviving boys died later compared to nonsurviving girls (adjusted mean survival time 23.0 [18.0, 27.9] vs. 20.7 [15.0, 26.3] days). LOHS and PAD assessed in 3,166 survivors displayed a continuous decrease over time (1978–1982 vs. 2013–2018: LOHS days 82.9 [79.3, 86.5] vs. 60.3 [58.4, 62.1] days); PAD 40.4 (39.9, 40.9) vs. 37.4 [37.1, 37.6] weeks). Girls had shorter LOHS than boys (69.4 [68.0, 70.8] vs. 73.0 [71.6, 74.4] days) and were discharged with lower PAD (38.6 [38.4, 38.8] vs. 39.2 [39.0, 39.4] weeks). <b><i>Discussion/Conclusions:</i></b> LOHS and PAD decreased over the last 40 years, while survival rates improved. Male sex was associated with longer LOHS, higher PAD, and higher mortality rates.
DOI: 10.6084/m9.figshare.14730393.v1
title: Supplementary Material for: Sex-Specific Long-Term Trends in Length of Hospital Stay, Postmenstrual Age at Discharge, and Survival in Very Low Birth Weight Infants

description: <b><i>Introduction:</i></b> In very low birth weight (&lt;1,500 g, VLBW) infants, morbidity and mortality have decreased substantially during the past decades, and both are known to be lower in girls than in boys. In this study, we assessed sex-specific changes over time in length of hospital stay (LOHS) and postmenstrual age at discharge (PAD), in addition to survival in VLBW infants. <b><i>Methods:</i></b> This is a single-center retrospective cohort analysis based on quality assurance data of VLBW infants born from 1978 to 2018. Estimation of sex-specific LOHS over time was based on infants discharged home from neonatal care or deceased. Estimation of sex-specific PAD over time was based on infants discharged home exclusively. Analysis of in-hospital survival was performed for all VLBW infants. <b><i>Results:</i></b> In 4,336 of 4,499 VLBW infants admitted from 1978 to 2018 with complete data (96.4%), survival rates improved between 1978–1982 and 1993–1997 (70.8 vs. 88.3%; hazard ratio (HR) 0.20, 95% confidence interval 0.14, 0.30) and remained stable thereafter. Boys had consistently higher mortality rates than girls (15 vs. 12%, HR 1.23 [1.05, 1.45]). Nonsurviving boys died later compared to nonsurviving girls (adjusted mean survival time 23.0 [18.0, 27.9] vs. 20.7 [15.0, 26.3] days). LOHS and PAD assessed in 3,166 survivors displayed a continuous decrease over time (1978–1982 vs. 2013–2018: LOHS days 82.9 [79.3, 86.5] vs. 60.3 [58.4, 62.1] days); PAD 40.4 (39.9, 40.9) vs. 37.4 [37.1, 37.6] weeks). Girls had shorter LOHS than boys (69.4 [68.0, 70.8] vs. 73.0 [71.6, 74.4] days) and were discharged with lower PAD (38.6 [38.4, 38.8] vs. 39.2 [39.0, 39.4] weeks). <b><i>Discussion/Conclusions:</i></b> LOHS and PAD decreased over the last 40 years, while survival rates improved. Male sex was associated with longer LOHS, higher PAD, and higher mortality rates.
DOI: 10.6084/m9.figshare.14730441
title: Supplementary Material for: Polypharmacy and the Progression of Chronic Kidney Disease: Korean Cohort Study for Outcome in Patients with Chronic Kidney Disease

description: <b><i>Introduction:</i></b> The renal hazard of polypharmacy has never been evaluated in predialysis chronic kidney disease (CKD) patients. <b><i>Objective:</i></b> We aimed to analyze the renal hazard of polypharmacy in predialysis CKD patients with stage 1–5. <b><i>Method:</i></b> The data of 2,238 patients from a large-scale multicenter prospective Korean study (2011–2016), excluding 325 patients with various missing data, were reviewed. Polypharmacy was defined as taking 6 or more medications at the time of enrollment; renal events were defined as a ≥50% decrease in kidney function from baseline values, doubling of the serum creatinine levels, or initiation of renal replacement treatment. Hazard ratio (HR) and 95% confidence interval (CI) were calculated using Cox proportional-hazard regression analysis. <b><i>Results:</i></b> Of the 1,913 patients, the mean estimated glomerular filtration rate was 53.6 mL/min/1.73 m<sup>2</sup>. The mean medication count was 4.1, and the prevalence of polypharmacy was 27.1%. During the average period of 3.6 years, 520 patients developed renal events (27.2%). Although increased medication counts were associated with increased renal hazard with HR (95% CI) of 1.056 (1.007–1.107, <i>p</i> = 0.025), even after adjusting for various confounders, adding comorbidity score and kidney function nullified the statistical significance. In mediation analysis, 55.6% (<i>p</i> = 0.016) of renal hazard in increased medication counts was mediated by the kidney function, and there was no direct effect of medication counts on renal event development. In subgroup analysis, the renal hazard of the medication counts was evident only in stage 1–3 of CKD patients (<i>p</i> for interaction = 0.014). <b><i>Conclusions:</i></b> We cannot identify the direct renal hazard of multiple medications, and most of the potential renal hazard was derived from intimate relationship with disease burden and kidney function.
DOI: 10.5281/zenodo.4898987
title: Engineering a Metathesis-Catalyzing Artificial Metalloenzyme Basedon HaloTag

description: Data underlying the figures in the publication “Engineering a Metathesis-Catalyzing Artificial Metalloenzyme Based on Halotag” published in <em>ACS Catal</em>., <strong>2021</strong>, 11, 6343−6347. The data contains an excel file with the curate data of the graphs from figures 2, 3 and 4. Data for Figure 2: Data processing: the data collection began from SDS gels (a representative gel is shown in the Supporting Information and at the bottom of this table). The total fluorescence of HaloTag was measured using the fluorescence-compatible gel imager. The signal in each lane was quantified with ImageJ. The signal was processed as indicated in the supporting information. Data for Figure 3: Data processing for fluorescence measurements: the data processing began with fluorescence intensities measured using a fluorescence plate reader. A calibration curve containing varying product concentrations was present on every plate. A linear fit of the calibration curve (fluorescence intensity vs. product concentration) was used to calculate the concentration of product in each experimental well. A sample of the calibration curves is supplied in the supporting information. The turnover number (TON) of each well was determined by dividing the product concentration by the concentration of the catalyst. Data processing for MS measurements: the data processing began with chromatogram from the GC-MS or the UPLC-MS. The peak areas corresponding to the desired product were integrated. A calibration curve containing varying product concentrations was completed for each desired product. A linear fit of the calibration curve (peak area vs. product concentration) was used to calculate the concentration of product in each reaction. A sample of the calibration curves is supplied in the supporting information. The turnover number (TON) of each well was determined by dividing the product concentration by the concentration of the catalyst. Data for Figure 4: Data processing for MS measurements: the data processing began with chromatogram from the UPLC-MS. The peak areas corresponding to the desired product were integrated. A calibration curve containing varying product concentrations was completed for each desired product. A linear fit of the calibration curve (peak area vs. product concentration) was used to calculate the concentration of product in each reaction. A sample of the calibration curves is supplied in the supporting information. The turnover number (TON) of each well was determined by dividing the product concentration by the concentration of the catalyst. The TON relative to wild-type enzyme was determined by dividing the TON of each variant by the TON of wild-type HT with the corresponding cofactor (Mes8 or N8).
DOI: 10.5281/zenodo.4898986
title: Engineering a Metathesis-Catalyzing Artificial Metalloenzyme Basedon HaloTag

description: Data underlying the figures in the publication “Engineering a Metathesis-Catalyzing Artificial Metalloenzyme Based on Halotag” published in <em>ACS Catal</em>., <strong>2021</strong>, 11, 6343−6347. The data contains an excel file with the curate data of the graphs from figures 2, 3 and 4. Data for Figure 2: Data processing: the data collection began from SDS gels (a representative gel is shown in the Supporting Information and at the bottom of this table). The total fluorescence of HaloTag was measured using the fluorescence-compatible gel imager. The signal in each lane was quantified with ImageJ. The signal was processed as indicated in the supporting information. Data for Figure 3: Data processing for fluorescence measurements: the data processing began with fluorescence intensities measured using a fluorescence plate reader. A calibration curve containing varying product concentrations was present on every plate. A linear fit of the calibration curve (fluorescence intensity vs. product concentration) was used to calculate the concentration of product in each experimental well. A sample of the calibration curves is supplied in the supporting information. The turnover number (TON) of each well was determined by dividing the product concentration by the concentration of the catalyst. Data processing for MS measurements: the data processing began with chromatogram from the GC-MS or the UPLC-MS. The peak areas corresponding to the desired product were integrated. A calibration curve containing varying product concentrations was completed for each desired product. A linear fit of the calibration curve (peak area vs. product concentration) was used to calculate the concentration of product in each reaction. A sample of the calibration curves is supplied in the supporting information. The turnover number (TON) of each well was determined by dividing the product concentration by the concentration of the catalyst. Data for Figure 4: Data processing for MS measurements: the data processing began with chromatogram from the UPLC-MS. The peak areas corresponding to the desired product were integrated. A calibration curve containing varying product concentrations was completed for each desired product. A linear fit of the calibration curve (peak area vs. product concentration) was used to calculate the concentration of product in each reaction. A sample of the calibration curves is supplied in the supporting information. The turnover number (TON) of each well was determined by dividing the product concentration by the concentration of the catalyst. The TON relative to wild-type enzyme was determined by dividing the TON of each variant by the TON of wild-type HT with the corresponding cofactor (Mes8 or N8).
DOI: 10.6084/m9.figshare.14730480.v1
title: test.zip

description: Validation datasets for training Dice-XMBD
DOI: 10.6084/m9.figshare.14730480
title: test.zip

description: Validation datasets for training Dice-XMBD
DOI: 10.6084/m9.figshare.14730570
title: Veronica_eriogyne.gbk

description: the complete chloroplast genome of Veronica eriogyne
DOI: 10.6084/m9.figshare.14730570.v1
title: Veronica_eriogyne.gbk

description: the complete chloroplast genome of Veronica eriogyne
DOI: 10.5281/zenodo.4898895
title: Novel Missense Mutation of SASH1 in a Chinese Family with Dyschromatosis Universalis Hereditaria

description: Dyschromatosis universalis hereditaria (DUH) is a pigmentary dermatosis characterized by generalized mottled macules with hypopigmention and hyperpigmention. <em>ABCB6</em> and <em>SASH1</em> are recently reported pathogenic genes related to DUH, and the aim of this study was to identify the causative mutations in a Chinese family with DUH. Sanger sequencing was performed to investigate the clinical manifestation and molecular genetic basis of these familial members of DUH. III5, III6, III9, III11,II4,II3,II9 were referred to GL01- GL06 in file respectively. Bioinformatics tools and multiple sequence alignment were used to analyse the pathogenicity of mutations.We performed Sanger sequencing on all exons in the SASH1 gene of II3, after confirmed the disease-causing mutation, we tested the presence of the mutation in other individuals.
DOI: 10.5281/zenodo.4898894
title: Novel Missense Mutation of SASH1 in a Chinese Family with Dyschromatosis Universalis Hereditaria

description: Dyschromatosis universalis hereditaria (DUH) is a pigmentary dermatosis characterized by generalized mottled macules with hypopigmention and hyperpigmention. <em>ABCB6</em> and <em>SASH1</em> are recently reported pathogenic genes related to DUH, and the aim of this study was to identify the causative mutations in a Chinese family with DUH. Sanger sequencing was performed to investigate the clinical manifestation and molecular genetic basis of these familial members of DUH. III5, III6, III9, III11,II4,II3,II9 were referred to GL01- GL06 in file respectively. Bioinformatics tools and multiple sequence alignment were used to analyse the pathogenicity of mutations.We performed Sanger sequencing on all exons in the SASH1 gene of II3, after confirmed the disease-causing mutation, we tested the presence of the mutation in other individuals.
DOI: 10.6084/m9.figshare.14730579
title: Supplementary Material for: Post hoc Analysis of a Randomized, Controlled, Phase 2 Study to Assess Response Rates with Chlormethine/Mechlorethamine Gel in Patients with Stage IA–IIA Mycosis Fungoides

description: <b><i>Background:</i></b> Mycosis fungoides (MF) is the most common form of cutaneous T-cell lymphoma. Patients can be treated using chlormethine gel, a skin-directed therapy developed and approved for MF. In the randomized, controlled 201 trial, chlormethine gel was found to be noninferior to equal-strength chlormethine ointment. However, there remains a need to gain more insight into outcome measures after treatment. <b><i>Objective:</i></b> The aim of this study was to further investigate the potential of chlormethine gel treatment through a novel post hoc analysis of the 201 trial data (NCT00168064). <b><i>Methods:</i></b> Patients were randomized to chlormethine gel or ointment; response assessments included Composite Assessment of Index Lesion Severity (CAILS) and total body surface area (BSA). In this post hoc analysis, additional subgroup response analyses were performed for stage IA/IB–IIA MF. Very good partial response (75 to &lt;100% improvement) was included as an additional response category. Time to response and overall response trends were determined. Finally, multivariate time-to-event analyses were performed to determine whether associations were observed between treatment frequency, response, and adverse events. <b><i>Results:</i></b> Response rates were significantly higher for patients with stage IA MF for CAILS (intent-to-treat [<i>p</i> = 0.0014] and efficacy-evaluable [EE; <i>p</i> = 0.0036] populations) and BSA (EE population [<i>p</i> = 0.0488]) treated with gel versus ointment. Time to first CAILS response and response trends were better for all-stage gel-treated patients overall. No association was seen between treatment frequency and response or occurrence of adverse events at the following visit. An association was observed between the occurrence of contact dermatitis and improved clinical response at the next visit (<i>p</i> = 0.0001). <b><i>Conclusion:</i></b> This post hoc analysis shows that treatment with chlormethine gel may result in higher and faster response rates compared with chlormethine ointment, which confirms and expands results reported in the original analysis. The incidence of contact dermatitis may potentially be a prognostic indicator for clinical response; this needs to be confirmed in a larger population.
DOI: 10.17632/mzmj53nssk.1
title: Cheating on Online Exam

description: Data about cheating on online exam for few related variables
DOI: 10.17632/9y6p7shshy.1
title: In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. Li et al

description: Supplemental Items
DOI: 10.17632/7fnt3nfhdv.1
title: Targeted metabolomics identifies high performing diagnostic and prognostic biomarkers for COVID-19

description: The data contain all the baseline information about participants in the study (COVID-19 patients and non-COVID-19) as well as metabolite measurements made by targeted metabolomics (raw data COVID-19_SR). We also provide the concentration data for metabolites expressed as mean (SD) or median (IQR).
DOI: 10.17632/nkt4k79spw.1
title: FFA treatment algorithm

description: Summary of studies evaluating the various treatment modalities for frontal fibrosing alopecia
DOI: 10.17632/sd554hbbjb.2
title: Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study - Supplement

description: Supplemental material for manuscript published in the Journal for the American Academy of Dermatology. https://doi.org/10.1016/j.jaad.2021.05.050